CDKN2A and neoplasm: The anti-proliferative effect of Met-enkephalin (OGF) was most likely related to the activation of p16INK4a (also known as cyclin-dependent kinase inhibitor 2A, a known tumor suppressor) and p21WAF1/CIP1 (also known as cyclin-dependent kinase inhibitor 1) [107].